Association of HRS-AKI with Mortality in Patients with Cirrhosis Requiring Renal Replacement Therapy: Results from the HRS-HARMONY Consortium.

IF 3.2 Q1 UROLOGY & NEPHROLOGY
Kidney360 Pub Date : 2024-09-30 DOI:10.34067/KID.0000000589
Augusto Cama-Olivares, Tianqi Ouyang, Tomonori Takeuchi, Shelsea A St Hillien, Jevon E Robinson, Raymond T Chung, Giuseppe Cullaro, Constantine J Karvellas, Josh Levitsky, Eric S Orman, Kavish R Patidar, Kevin R Regner, Danielle L Saly, Deirdre Sawinski, Pratima Sharma, J Pedro Teixeira, Nneka N Ufere, Juan Carlos Q Velez, Hani M Wadei, Nabeel Wahid, Andrew S Allegretti, Javier A Neyra, Justin M Belcher
{"title":"Association of HRS-AKI with Mortality in Patients with Cirrhosis Requiring Renal Replacement Therapy: Results from the HRS-HARMONY Consortium.","authors":"Augusto Cama-Olivares, Tianqi Ouyang, Tomonori Takeuchi, Shelsea A St Hillien, Jevon E Robinson, Raymond T Chung, Giuseppe Cullaro, Constantine J Karvellas, Josh Levitsky, Eric S Orman, Kavish R Patidar, Kevin R Regner, Danielle L Saly, Deirdre Sawinski, Pratima Sharma, J Pedro Teixeira, Nneka N Ufere, Juan Carlos Q Velez, Hani M Wadei, Nabeel Wahid, Andrew S Allegretti, Javier A Neyra, Justin M Belcher","doi":"10.34067/KID.0000000589","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While AKI requiring renal replacement therapy (AKI-RRT) is associated with increased mortality in heterogeneous inpatient populations, the epidemiology of AKI-RRT in hospitalized patients with cirrhosis is not fully known. Herein, we evaluated the association of etiology of AKI with mortality in hospitalized patients with cirrhosis and AKI-RRT in a multicentric contemporary cohort.</p><p><strong>Methods: </strong>This is a multicenter retrospective cohort study using data from the HRS-HARMONY consortium, which included 11 U.S. hospital network systems. Consecutive adult patients admitted in 2019 with cirrhosis and AKI-RRT were included. The primary outcome was 90-day mortality, and the main independent variable was AKI etiology, classified as hepatorenal syndrome (HRS-AKI) vs. other (non-HRS-AKI). AKI etiology was determined by at least two independent adjudicators. We performed Fine and Gray sub-distribution hazard analyses adjusting for relevant clinical variables.</p><p><strong>Results: </strong>Of 2,063 hospitalized patients with cirrhosis and AKI, 374 (18.1%) had AKI-RRT. Among these, 65 (17.4%) had HRS-AKI and 309 (82.6%) non-HRS-AKI, which included ATN in most cases (62.6%). Continuous RRT (CRRT) was used as the initial modality in 264 (71%) of patients, while intermittent hemodialysis (IHD) was utilized in 108 (29%). The HRS-AKI (vs. non-HRS-AKI) group received more vasoconstrictors for HRS management (81.5% vs. 67.9%), while the non-HRS-AKI group received more mechanical ventilation (64.3% vs. 50.8%) and more CRRT (vs. IHD) as the initial RRT modality (73.9% vs. 56.9%). In the adjusted model, HRS-AKI (vs. non-HRS-AKI) was not independently associated with increased 90-day mortality (sHR=1.36, 95% CI: 0.95-1.94).</p><p><strong>Conclusions: </strong>In this multicenter contemporary cohort of hospitalized adult patients with cirrhosis and AKI-RRT, HRS-AKI was not independently associated with an increased risk of 90-day mortality when compared to other AKI etiologies. The etiology of AKI appears less relevant than previously considered when evaluating the prognosis of hospitalized adult patients with cirrhosis and AKI requiring RRT.</p>","PeriodicalId":17882,"journal":{"name":"Kidney360","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34067/KID.0000000589","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: While AKI requiring renal replacement therapy (AKI-RRT) is associated with increased mortality in heterogeneous inpatient populations, the epidemiology of AKI-RRT in hospitalized patients with cirrhosis is not fully known. Herein, we evaluated the association of etiology of AKI with mortality in hospitalized patients with cirrhosis and AKI-RRT in a multicentric contemporary cohort.

Methods: This is a multicenter retrospective cohort study using data from the HRS-HARMONY consortium, which included 11 U.S. hospital network systems. Consecutive adult patients admitted in 2019 with cirrhosis and AKI-RRT were included. The primary outcome was 90-day mortality, and the main independent variable was AKI etiology, classified as hepatorenal syndrome (HRS-AKI) vs. other (non-HRS-AKI). AKI etiology was determined by at least two independent adjudicators. We performed Fine and Gray sub-distribution hazard analyses adjusting for relevant clinical variables.

Results: Of 2,063 hospitalized patients with cirrhosis and AKI, 374 (18.1%) had AKI-RRT. Among these, 65 (17.4%) had HRS-AKI and 309 (82.6%) non-HRS-AKI, which included ATN in most cases (62.6%). Continuous RRT (CRRT) was used as the initial modality in 264 (71%) of patients, while intermittent hemodialysis (IHD) was utilized in 108 (29%). The HRS-AKI (vs. non-HRS-AKI) group received more vasoconstrictors for HRS management (81.5% vs. 67.9%), while the non-HRS-AKI group received more mechanical ventilation (64.3% vs. 50.8%) and more CRRT (vs. IHD) as the initial RRT modality (73.9% vs. 56.9%). In the adjusted model, HRS-AKI (vs. non-HRS-AKI) was not independently associated with increased 90-day mortality (sHR=1.36, 95% CI: 0.95-1.94).

Conclusions: In this multicenter contemporary cohort of hospitalized adult patients with cirrhosis and AKI-RRT, HRS-AKI was not independently associated with an increased risk of 90-day mortality when compared to other AKI etiologies. The etiology of AKI appears less relevant than previously considered when evaluating the prognosis of hospitalized adult patients with cirrhosis and AKI requiring RRT.

HRS-AKI 与需要肾脏替代治疗的肝硬化患者死亡率的关系:HRS-HARMONY 联合会的研究结果。
背景:需要肾脏替代治疗(AKI-RRT)的AKI与不同住院人群的死亡率增加有关,但肝硬化住院患者AKI-RRT的流行病学尚不完全清楚。在此,我们在一个多中心当代队列中评估了 AKI 病因与肝硬化住院患者死亡率和 AKI-RRT 的关系:这是一项多中心回顾性队列研究,使用的数据来自HRS-HARMONY联盟,该联盟包括11个美国医院网络系统。研究纳入了 2019 年入院的肝硬化和 AKI-RRT 连续成人患者。主要结果是90天死亡率,主要自变量是AKI病因,分为肝肾综合征(HRS-AKI)与其他(非HRS-AKI)。AKI 病因至少由两名独立评审员确定。我们进行了Fine和Gray子分布危险分析,并对相关临床变量进行了调整:在 2063 名住院的肝硬化合并 AKI 患者中,374 人(18.1%)接受了 AKI-RRT 治疗。其中,65人(17.4%)患有HRS-AKI,309人(82.6%)患有非HRS-AKI,其中大部分病例(62.6%)患有ATN。264例(71%)患者的初始治疗方式为持续性血液透析(CRRT),108例(29%)患者的初始治疗方式为间歇性血液透析(IHD)。HRS-AKI(与非 HRS-AKI)组接受更多血管收缩剂进行 HRS 管理(81.5% 对 67.9%),而非 HRS-AKI组接受更多机械通气(64.3% 对 50.8%)和更多 CRRT(对 IHD)作为初始 RRT 方式(73.9% 对 56.9%)。在调整模型中,HRS-AKI(vs.non-HRS-AKI)与90天死亡率增加无独立关联(sHR=1.36,95% CI:0.95-1.94):在这一多中心当代住院成人肝硬化患者和 AKI-RRT 队列中,与其他 AKI 病因相比,HRS-AKI 与 90 天死亡风险的增加无关。在评估肝硬化合并需要进行 RRT 的 AKI 住院成年患者的预后时,AKI 的病因似乎没有以前考虑的那么重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Kidney360
Kidney360 UROLOGY & NEPHROLOGY-
CiteScore
3.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信